Hollie Franklin, Author at Drugs in Context

Symptomatic uncomplicated diverticular disease management: an innovative food-grade formulation of Curcuma longa and Boswellia serrata extracts

Attilio Giacosa MD, PhD, Antonella Riva PhD, Giovanna Petrangolini MSc, Pietro Allegrini MSc, Teresa Fazia PhD, Luisa Bernardinelli PhD, Clara Gasparri MSc, Milena Anna Faliva PhD, Gabriella Peroni BSc, Simone Perna PhD, Mariangela Rondanelli MD, PhD

Article Type

Original Research

Published

14 Dec 2020

This article investigates the potential role of a new delivery formulation of the association of curcumin and boswellia phytosome extracts in symptomatic uncomplicated colonic diverticular disease.

Progestogens as a component of menopausal hormone therapy: the right molecule makes the difference

John C Stevenson MB BS, FRCP, FESC, MFSEM, Serge Rozenberg MD, PhD, Silvia Maffei MD, Christian Egarter Prof Dr Med, Petra Stute Prof Dr Med, Thomas Römer Prof Dr Med

Article Type

Review

Published

02 Dec 2020

This narrative review examines the role of progestogens in MHT, with the aim of providing practical recommendations for prescribing physicians.

Ertugliflozin in the treatment of type 2 diabetes mellitus

Joel C Marrs PharmD, MPH, Sarah L Anderson PharmD

Article Type

Review

Published

30 Nov 2020

This narrative review aims to present and discuss the efficacy, safety, cardiovascular, and renal outcomes related to the use of ertugliflozin in Type 2 diabetes.

Acute bacterial sinusitis in children: an updated review

Alexander KC Leung MBBS, FRCPC, FRCP (UK and Irel), FRCPCH, FAAP, Kam Lun Hon MD, FAAP, FCCM, Winnie CW Chu MD, FRCR

Article Type

Review

Published

23 Nov 2020

This article is an updated narrative review on the evaluation, diagnosis, and management of acute bacterial sinusitis.

Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib

Novin Nezamololama, BSc, MSc, Keira Fieldhouse, BSc, Kristy Metzger, BSc, Melinda Gooderham, MD, MSc, FRCPC

Article Type

Review

Published

16 Nov 2020

This review summarizes the clinical data available from various trials and reports on the safety and efficacy of abrocitinib, baricitinib, and upadacitinib, the three oral systemic JAK inhibitors used in the treatment of atopic dermatitis.